Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market. Ultimately, Boston Scientific's earnings ...

Boston Scientific’s fourth-quarter profit and sales climbed but the medical-device maker issued a soft forecast for the year, sending shares down in premarket trading. The company logged earnings of ...

Boston Scientific, one of the largest medical technology companies in the nation, is vacating its Minnetonka campus for good in one year, the listing said, opening up 24 acres for sale. The property ...

Feb 4 (Reuters) - Boston Scientific (BSX.N), opens new tab on Wednesday reported lower-than-expected quarterly sales in its key electrophysiology division, dragging the medical device maker's shares ...

The Boston Scientific Analyst: Analyst Mike Matson maintained a Buy rating, but slashed the price target from $121 to $97. The Boston Scientific Thesis: The company reported revenue of $5.286 billion ...

Boston Scientific (BSX) lost ~9% in the premarket on Wednesday after the MedTech giant indicated an underwhelming outlook for 2026 with its Q4 2025 results, which, however, beat Street forecasts ...

Boston Scientific’s electrophysiology business stumbled as competition from Medtronic, Johnson & Johnson, Abbott, and others in the pulsed-field ablation (PFA) space intensified. Marie Thibault, a ...

Despite growing sales and adjusted EPS by 16% and 14% in Q4 -- easily beating Wall Street’s estimates -- Boston Scientific stock dropped 18% on Wednesday due to “weak” guidance. More specifically, the ...

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income ...

The company's earnings came in at $672 million, or $0.45 per share. This compares with $566 million, or $0.38 per share, last year. Excluding items, Boston Scientific Corp reported adjusted earnings ...